{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:14:20Z","timestamp":1793182460724,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019385","name":"Kurume University","doi-asserted-by":"publisher","award":["Startup Award for Researchers with Life Events"],"award-info":[{"award-number":["Startup Award for Researchers with Life Events"]}],"id":[{"id":"10.13039\/100019385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00535-025-02242-y","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T22:19:51Z","timestamp":1742249991000},"page":"891-904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6571-9874","authenticated-orcid":false,"given":"Tsubasa","family":"Tsutsumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Tatsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuji","family":"Maeshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tobita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemi","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitomi","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Kawanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayashi","family":"Syokita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoari","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sakugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshioki","family":"Yoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Fuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi M.","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2242_CR1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"key":"2242_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","volume":"28","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28:841\u201350.","journal-title":"Clin Mol Hepatol"},{"key":"2242_CR3","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640\u20135.","journal-title":"Circulation"},{"key":"2242_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/obr.12407","volume":"17","author":"L Li","year":"2016","unstructured":"Li L, Liu DW, Yan HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17:510\u20139.","journal-title":"Obes Rev"},{"key":"2242_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862\u201373.","journal-title":"J Hepatol"},{"key":"2242_CR6","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy V, Tavaglione F, Chatelain E, et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3624\u201333.","journal-title":"Nat Med"},{"key":"2242_CR7","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi O, De Vincentis A, Tavaglione F, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3614\u201323.","journal-title":"Nat Med"},{"key":"2242_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"61\u201371","key":"2242_CR9","volume":"19","author":"M Balakrishnan","year":"2021","unstructured":"Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(61\u201371): e15.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2242_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457\u201369.","journal-title":"Hepatology"},{"key":"2242_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"2242_CR12","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/hepr.13947","volume":"53","author":"H Fujii","year":"2023","unstructured":"Fujii H, Suzuki Y, Sawada K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: a large-scale multicenter retrospective study. Hepatol Res. 2023;53:1059\u201372.","journal-title":"Hepatol Res"},{"key":"2242_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.5551\/jat.GL2017","volume":"25","author":"M Kinoshita","year":"2018","unstructured":"Kinoshita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25:846\u2013984.","journal-title":"J Atheroscler Thromb"},{"key":"2242_CR14","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes\u20142023. Diabetes Care. 2023;46:S19\u201340.","journal-title":"Diabetes Care"},{"key":"2242_CR15","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, et al. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2242_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.gastha.2024.08.006","volume":"3","author":"Y Kamada","year":"2024","unstructured":"Kamada Y, Fujii H, Suzuki Y, et al. Clinical characteristics of steatotic liver disease categories in a large cohort of Japanese health checkup participants. Gastro Hep Adv. 2024;3:1148\u201356.","journal-title":"Gastro Hep Adv"},{"key":"2242_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361\u201387.","journal-title":"Stat Med"},{"key":"2242_CR18","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"2242_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1507\/endocrj.EJ23-0593","volume":"71","author":"W Ogawa","year":"2024","unstructured":"Ogawa W, Hirota Y, Miyazaki S, et al. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J. 2024;71:223\u201331.","journal-title":"Endocr J"},{"key":"2242_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4103\/ijd.IJD_201_17","volume":"62","author":"A Hazra","year":"2017","unstructured":"Hazra A, Gogtay N. Biostatistics series module 9: survival analysis. Indian J Dermatol. 2017;62:251\u20137.","journal-title":"Indian J Dermatol"},{"key":"2242_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","volume":"56","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56:951\u201363.","journal-title":"J Gastroenterol"},{"key":"2242_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2242_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12876-022-02393-9","volume":"22","author":"M Kuang","year":"2022","unstructured":"Kuang M, Lu S, Xie Q, et al. Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population. BMC Gastroenterol. 2022;22:311.","journal-title":"BMC Gastroenterol"},{"key":"2242_CR24","doi-asserted-by":"publisher","first-page":"1411802","DOI":"10.3389\/fnut.2024.1411802","volume":"11","author":"H Zou","year":"2024","unstructured":"Zou H, Ma X, Pan W, et al. Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population. Front Nutr. 2024;11:1411802.","journal-title":"Front Nutr"},{"key":"2242_CR25","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu V, Boursier J. Fibrosis AGftSoL. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2024;80:e51\u20132.","journal-title":"J Hepatol"},{"key":"2242_CR26","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20:e573\u201382.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2242_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/apt.14112","volume":"46","author":"S Sookoian","year":"2017","unstructured":"Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46:85\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"2242_CR28","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/hep4.1975","volume":"6","author":"Y Cho","year":"2022","unstructured":"Cho Y, Chang Y, Ryu S, et al. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. Hepatol Commun. 2022;6:2238\u201352.","journal-title":"Hepatol Commun"},{"key":"2242_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12944-024-02100-5","volume":"23","author":"C Liu","year":"2024","unstructured":"Liu C, Li N, Sheng D, et al. Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population. Lipids Health Dis. 2024;23:104.","journal-title":"Lipids Health Dis"},{"key":"2242_CR30","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519\u201323.","journal-title":"Science"},{"key":"2242_CR31","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1210\/jc.2015-2649","volume":"100","author":"C Pramfalk","year":"2015","unstructured":"Pramfalk C, Pavlides M, Banerjee R, et al. Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men. J Clin Endocrinol Metab. 2015;100:4425\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"2242_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5551\/jat.13.143","volume":"13","author":"A Al-Mahmood","year":"2006","unstructured":"Al-Mahmood A, Ismail A, Rashid F, et al. Isolated hypertriglyceridemia: an insulin-resistant state with or without low HDL cholesterol. J Atheroscler Thromb. 2006;13:143\u20138.","journal-title":"J Atheroscler Thromb"},{"key":"2242_CR33","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3389\/fphys.2019.01486","volume":"10","author":"AM Nauli","year":"2019","unstructured":"Nauli AM, Matin S. Why do men accumulate abdominal visceral fat? Front Physiol. 2019;10:1486.","journal-title":"Front Physiol"},{"key":"2242_CR34","doi-asserted-by":"publisher","first-page":"1316982","DOI":"10.3389\/fphys.2023.1316982","volume":"14","author":"AM Nauli","year":"2023","unstructured":"Nauli AM, Phan A, Tso P, et al. The effects of sex hormones on the size of intestinal lipoproteins. Front Physiol. 2023;14:1316982.","journal-title":"Front Physiol"},{"key":"2242_CR35","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0026-0495(90)90297-P","volume":"39","author":"JC Seidell","year":"1990","unstructured":"Seidell JC, Bjorntorp P, Sjostrom L, et al. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897\u2013901.","journal-title":"Metabolism"},{"key":"2242_CR36","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/j.2040-4603.2018.tb00043.x","volume":"8","author":"A Tchernof","year":"2018","unstructured":"Tchernof A, Brochu D, Maltais-Payette I, et al. Androgens and the regulation of adiposity and body fat distribution in humans. Compr Physiol. 2018;8:1253\u201390.","journal-title":"Compr Physiol"},{"key":"2242_CR37","first-page":"825","volume":"116","author":"KG Parhofer","year":"2019","unstructured":"Parhofer KG, Laufs U. The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int. 2019;116:825\u201332.","journal-title":"Dtsch Arztebl Int"},{"key":"2242_CR38","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/s41591-024-02951-6","volume":"30","author":"KM Bermingham","year":"2024","unstructured":"Bermingham KM, Linenberg I, Polidori L, et al. Effects of a personalized nutrition program on cardiometabolic health: a randomized controlled trial. Nat Med. 2024;30:1888\u201397.","journal-title":"Nat Med"},{"key":"2242_CR39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.mcna.2024.03.005","volume":"108","author":"J Wright","year":"2024","unstructured":"Wright J, Subramanian S. Therapy for hyperlipidemia. Med Clin North Am. 2024;108:881\u201394.","journal-title":"Med Clin North Am"},{"key":"2242_CR40","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/hepr.13571","volume":"50","author":"Y Seko","year":"2020","unstructured":"Seko Y, Yamaguchi K, Umemura A, et al. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: a single-arm, pilot study. Hepatol Res. 2020;50:1328\u201336.","journal-title":"Hepatol Res"},{"key":"2242_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2242_CR42","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ajg.2017.44","volume":"112","author":"M Sarkar","year":"2017","unstructured":"Sarkar M, Wellons M, Cedars MI, et al. Testosterone levels in pre-menopausal women are associated with nonalcoholic fatty liver disease in midlife. Am J Gastroenterol. 2017;112:755\u201362.","journal-title":"Am J Gastroenterol"},{"key":"2242_CR43","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3390\/cells10092502","volume":"10","author":"S Della Torre","year":"2021","unstructured":"Della Torre S. Beyond the X factor: relevance of sex hormones in NAFLD pathophysiology. Cells. 2021;10:2502.","journal-title":"Cells"},{"key":"2242_CR44","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/gme.0b013e3181f6480e","volume":"18","author":"GA Woodard","year":"2011","unstructured":"Woodard GA, Brooks MM, Barinas-Mitchell E, et al. Lipids, menopause, and early atherosclerosis in study of women\u2019s health across the nation heart women. Menopause. 2011;18:376\u201384.","journal-title":"Menopause"},{"key":"2242_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/ATVBAHA.120.315355","volume":"41","author":"SR El Khoudary","year":"2021","unstructured":"El Khoudary SR, Chen X, Nasr AN, et al. HDL (high-density lipoprotein) subclasses, lipid content, and function trajectories across the menopause transition: SWAN-HDL study. Arterioscler Thromb Vasc Biol. 2021;41:951\u201361.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2242_CR46","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.2337\/dc13-1048","volume":"36","author":"Y Heianza","year":"2013","unstructured":"Heianza Y, Arase Y, Kodama S, et al. Effect of postmenopausal status and age at menopause on type 2 diabetes and prediabetes in Japanese individuals: Toranomon Hospital health management center study 17 (TOPICS 17). Diabetes Care. 2013;36:4007\u201314.","journal-title":"Diabetes Care"},{"key":"2242_CR47","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/CIRCRESAHA.121.319424","volume":"130","author":"S Samargandy","year":"2022","unstructured":"Samargandy S, Matthews KA, Brooks MM, et al. Trajectories of blood pressure in midlife women: does menopause matter? Circ Res. 2022;130:312\u201322.","journal-title":"Circ Res"},{"key":"2242_CR48","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1152\/ajpregu.00057.2023","volume":"325","author":"OO Badmus","year":"2023","unstructured":"Badmus OO, Kipp ZA, Bates EA, et al. Loss of hepatic PPARalpha in mice causes hypertension and cardiovascular disease. Am J Physiol Regul Integr Comp Physiol. 2023;325:R81\u201395.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2242_CR49","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.2337\/db10-0554","volume":"59","author":"MI Goran","year":"2010","unstructured":"Goran MI, Walker R, Le KA, et al. Effects of PNPLA3 on liver fat and metabolic profile in hispanic children and adolescents. Diabetes. 2010;59:3127\u201330.","journal-title":"Diabetes"},{"key":"2242_CR50","doi-asserted-by":"publisher","first-page":"909","DOI":"10.5604\/01.3001.0010.5282","volume":"16","author":"LA Martinez","year":"2017","unstructured":"Martinez LA, Larrieta E, Kershenobich D, et al. The expression of PNPLA3 polymorphism could be the key for severe liver disease in NAFLD in hispanic population. Ann Hepatol. 2017;16:909\u201315.","journal-title":"Ann Hepatol"},{"key":"2242_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16088","volume":"45","author":"A Cherubini","year":"2025","unstructured":"Cherubini A, Rosso C, Della TS. Sex-specific effects of PNPLA3 I148M. Liver Int. 2025;45: e16088.","journal-title":"Liver Int"},{"key":"2242_CR52","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/hepr.13453","volume":"50","author":"K Hirota","year":"2020","unstructured":"Hirota K, Kawaguchi T, Koya S, et al. Clinical utility of the liver frailty index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma. Hepatol Res. 2020;50:330\u201341.","journal-title":"Hepatol Res"},{"key":"2242_CR53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/geriatrics8060116","volume":"8","author":"RR Porter","year":"2023","unstructured":"Porter RR, Sparks JR, Durstine JL, et al. Effect of exercise training on lipoprotein subclass particle concentrations and sizes in older women: results from a randomized controlled trial. Geriatrics (Basel). 2023;8:116.","journal-title":"Geriatrics (Basel)"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02242-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02242-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02242-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:05:04Z","timestamp":1773068704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02242-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02242-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"T.K. received lecture fees from Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., ASKA Pharmaceutical Co., Ltd., AbbVie GK., EA Pharma Co., Ltd. M.K. received a research grant from Fuji Rebio. A.N. received honorariums from EA Pharma Co., Ltd, Mochida Pharmaceutical Co., LTD., Kowa Company, Ltd., Taisho Pharmaceutical Co., Ltd., and Viatris; a fee from EA Pharma Co., Ltd.; and a research grant from EA Pharma Co., Ltd, Mochida Pharmaceutical Co., LTD., Kowa Company, Ltd., and Gilead Science. H.Y. received lecture fees from Otsuka Pharmaceutical Co., Ltd., Asuka Pharmaceutical Co., Ltd., Gilead Sciences, Novel Pharmaceutical, Taisho Pharmaceutical Co., Ltd., and AbbVie Inc. H.T. received lecture fees from Novonordisk, Kowa Company, Ltd., and Taisho Pharmaceutical Co., Ltd., and a fee for writing from an undisclosed company. M.E.R. provides scientific consulting for Akero, 89Bio, Boehringer Ingelheim, Intercept Pharmaceuticals, Histoindex, Madrigal, NGM Biopharmaceuticals, Novo Nordisk, Eli Lilly, Sagimet Biosciences, Sonic Incytes, Cytodyn, and GSK and serves on the scientific executive boards of Akero, Madrigal, and Novo Nordisk. M.R.C. is employed by Madrigal and previously provided scientific consulting for Novo Nordisk, 89Bio, Northsea, Merck, Akero, Cytodyn, Pfizer, Aligos, Sagimet, and Eli Lilly. Y.Su. received a research grant from an undisclosed company and scholarship grants from Takeda and Sysmex. The other authors have no conflicts of interest relevant to this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}